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* ** *** 
Inhibition of 5-lipoxygenase by anthralin (1) and 41 derivatives is determin-
ed: the acids 38 and 39, the lactones 40-42 and 9-anthrone (8) are the most 
potent inhibitors, the lactone 41 reaching the efficacy of nordihydroguaiaretic 
acid (NDGA). The results were correlated with the hydrophilic/lipophilic 
balance of the test compounds and their clinical efficacy as far as known. 
There is no correlation between the "minimum structure" of Krebs and 
SchalteggeP^ concerning antipsoriatic activity and the inhibitory effects 
against 5-lipoxygenase. 
Dithranol-Derivate: Hemmung der 5-Lipoxygenase und antipsoriatische 
Wirksamkeit 
Die Hemmung der 5-Lipoxygenase durch Dithranol (1) und 41 Derivate wird 
bestimmt: die Säuren 38 und 39, die Laktone 40-42 und 9-Anthron (8) sind 
die stärksten Inhibitoren, das Lakton 41 erreicht die Wirksamkeit der Nordih-
ydroguajaretsäure. Die Ergebnisse werden mit den hydrophilen/lipophilen 
Eigenschaften der Verbindungen und - soweit bekannt - mit deren klinischer 
Wirksamkeit in Beziehung gesetzt: es besteht keine Korrelation zwischen der 
sog. "antipsoriatischen Minimalstruktur" nach Krebs und SchalteggeP^ und 
der Hemm wirkung auf die 5-Lipoxygenase. 
Psoriasis is a common chronic inflammatory and proliferative skin dis-
ease with unknown aetiology. An important feature is the abnormal meta-
bolism of arachidonic acid, particularly by the lipoxygenase pathways. Le-
sional skin contains increased concentrations of arachidonic acid, 12-HETE 
and LTB 4 , whereas the cyclooxygenase-products P G F ^ and PGE2 are only 
modestly elevated1*. L T B 4 and 12-HETE are potent chemoattractans for 
human polymorphonuclear leukocytes (PMNs)2), which are part of a char-
acteristic inflammatory infiltrate and were suggested to play an important 
physiologic role in cutaneous lesion of psoriasis3*. 
Anthralin (dithranol), an effective topical antipsoriatic 
remedy, inhibits the 5- and 12-lipoxygenase pathways of 
arachidonic acid metabolism in vitro and various functional 
responses of human neutrophils4'5^. Whether these proper-
ties are relevant to the clinical efficacy of the drug has not 
yet been established. 
In the present study structure-activity relationships con-
cerning the in vitro 5-lipoxygenase inhibitory activity of 
various anthrone derivatives and related compounds were 
investigated. The results were compared with the antipsori-
atic properties of the compounds according to the "mini-
mum structure" concept by Krebs and SchalteggeP\ 
Materials and Methods 
Calcium ionophore A 23187, arachidonic acid (99% pure), nordihydro-
guaiaretic acid and Histo Paque 1077: Sigma Chemie, München; Standard 
LTB 4 ,5-HETE, 5S, 12S-diHETE, and PGB 2: Paesel GmbH, Frankfurt. 
The test compounds were purchased or synthesized by described proce-
dures (vide infra) or by reduction of the corresponding anthraquinones 
according to Auterhojf\ purification by column chromatography on silica 
gel or crystallization. Analytical data are in accord with those described. 
Anthralin8) (1); l-acetoxy-9-anthrone9) (2); l,8-diacetoxy-9-anthrone10) 
(3); l-hydroxy-8-methoxy-9-anthronen) (4); l,8-dimethoxy-9-anthronen) 
(5); l-amino-9-anthrone12) (6) from 1-amino-anthraquinone (Aldrich); 1-
hydroxy-9-anthrone13) (7); 9-anthrone (8) (Janssen); l,8-dichloro-9-an-
throne14) (9); benzophenone (10) (Merck); 2,2'-dihydroxybenzophenone 
(11) (EGA-Chemie); (9,10-dihydro-1,8-dihydroxy-9-oxo-anthracen-2-yl)-
acetic acid 1 5 ) (12); 3-(9,10-dihydro-1,8-dihydroxy-9-oxo-anthracen-2-y 1)-
propionic acid 1 5 ) (13); 2,7-bis-(carboxymethyl)-l,8-dihydroxy-9(10//)-an-
thracenone15) (14); l,8-dihydroxy-2-methoxycarbonylmethyl-9(10//)-an-
thracenone16) (15); l,8-dihydroxy-2-methoxycarbonylethyl-9(10//)-an-
thracenone16) (16); aloeemodin-anthrone17) (17); crysarobin18) (18) from 
crysophanic acid (Aldrich); danthrone (19) (Aldrich); 1,8-dimethoxy-an-
thraquinone19) (20); 9,10-anthraquinone (21) (Aldrich); l,5-dihydroxy-9-
anthraquinone (22) (Aldrich); l,8,9-triacetoxyanthracene9) (23); 1,8,9-tri-
methoxyanthracene10) (24); l,5-dihydroxy-9-anthrone20) (25) from 22; 
bianthrone8) (1,8,1 \8,-tetrahydroxybianthron) (26); l,8,10-trihydroxy-9-
anthrone21) (27); 9,10-dihydroanthracene (28) (Aldrich); 10-bromo-l,8-di-
hydroxy-9( 1 C//)-anthracenone9) (29); l,8-dihydroxy-10-ethyl-9(10//)-an-
thracenone22) (30); l,8-dihydroxy-10,10-dipropyl-9(10//)-anthracenone10) 




hydroxy-10-(3 '-benzyloxycarbonyl-1 *-oxopropyl)-9( 1 OF/)-anthracenone24) 
(36); 4-(9,l(Mihydro-l,8-dmydroxy-9-oxo-^ 
acid24* (37);5-(9,10-dmydro-l,8-dihydroxy-9-oxo-anthracen-10-yl)-5-oxo-
pentylic acid 2 4 ) (38); 6-(9,10-dihydro-1,8-dmydroxy-9-oxo-anthracen-10-
yl)-6-oxohexylic acid24* (39); l,8-dihydroxy-10-(dihydro-5,-oxo-2,(3*//)-
fui^yliden)-9(l(W)-anthracenone15) (40); l,8-dihydroxy-10-(tetrahydro-
6'-oxo-2W-pyKm-2,-yliden)-9(lQ^-anthracenone, analogously to24* (41); 
l,8-dihya>oxy-10-(7,-oxo-oxerjan-2,-yliden)-9(l(H)-anthi^e 
Test compounds were dissolved in DMSO (p.a.) immediately before use. 
Partition coefficients were determined by a HPLC method25 ,26 ,27*. Sta-
tionary phase: Nucleosil 100 C18 7-u.M; mobile phase: methanol/ 
water/acetic acid (77:23:0.1 by vol., pH 5.5); flow rate: 1 ml/min; stand-
ards: benzoic acid, benzophenone, naphthalene, anthracene, 1,8-diacetoxy-
9-anthrone. Results were calculated by means of 3 independent experi-
ments. 
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Cell Preparation 
Bovine polymorphonuclear leukocytes were isolated as described by 
Walstra et a l . 2 8 a ) . Na2~EDTA (0.077 M , 0.1 1 per 1 blood) was used instead 
of trisodium citrate as anticoagulating agent and at the end of the procedure 
contaminating platelets were removed by repeated centrifugations at 100 x 
gfor20min 2 8 b ) . 
Incubation procedures 
Polymorphonuclear leukocytes were suspended in phosphate-buffered 
saline, pH 7.4, at a final concentration of 1 x 107 cells/ml. 2.4 ml of this 
suspension were preincubated with the anthracene-derivatives by adding 10 
ul of a DMSO stock solution and shaking in a water bath at 37°C fori 5 
min. Control samples contained DMSO alone. Thereafter CaCl 2 (2 mM) as 
well as C a 2 + ionophore A 23187 (20 u,M) were added. Incubation was 
carried out for 5 min at 37°C and stopped by addition of a mixture of 
acetonitril and methanol (1:1) containing 60 ng prostaglandin B 2 (PGB2) 
(internal standard) and NDGA (24 u,M) as radical scavenger. The samples 
were cooled in an ice bath for 20 min and centrifuged at 4000 x g for 15 
min. After centrifugation the supematants were collected and stored at 
-20°C until they were analyzed by reversed-phase-HPLC. 
Reversed-Phase High-Performance Liquid Chromatography2® 
The cell supernatant was applied to an octadecyl (C 1 8) (250 x 4 mm) 
reversed-phase extraction column, which had previously been washed with 
methanol and water according to the manufacturer's instructions. After 
applying the supernatant to the column and washing with water (10 ml) the 
adsorbed leukotrienes were eluted with 3 ml methanol. Recovery for all 
leukotrienes was found to be better than 80%. After addition of 3 ml water 
to the methanolic solutions of leukotrienes aliquots of 2 ml were directly 
subjected to reversed-phase-HPLC. 
High-performance liquid chromatography was performed with a 250 x 4 
mm Nucleosil 100 C 1 8 7-^iM column, attached to a Kontron 420 pump and 
a Kontron Uvikon 735 LC UV detector. 
Isocratic elution was carried out with tetrahydrofuran/methanol/water/ 
acetic acid (25:30:45:0.1 by vol.) which had been brought to pH 5.5 with 
ammonia28). A flow rate of 0.9 ml/min was used and the detection was at 
270 nm. 5-HETE was detected at 232 nm with methanol/water/acetic acid 
(77:23:0.1 by vol., pH 5.5) and a flow rate of 1 ml/min. 
Peak areas were integrated with a Merck-Hitachi D-2000 integrator by 
relation to external standards of authentic samples. The recovery of the 
internal standard PGB 2 was used to correct for losses during sample prep-
aration. Molar absorption coefficients (M" 1 cm*1) of 28,650 for PGB 2 and 
50,000 for L T B 4 at 270 nm and 29,500 for 5-HETE at 232 nm were used6). 
Statistics 
The test compounds were studied for their influence on 
the LTB 4 - or 5-HETE production of bovine polymorphonu-
clear leukocytes. Product formation in the treatment groups 
(N = 2, range < 10%) was compared to the mean level in the 
control group (N = 6-8; SD < 5%). Results are expressed as 
percent inhibition. 
Results 
In Fig. 1 a typical reversed-phase HPLC-chromatogram of 
the leukotrienes formed by bovine polymorphonuclear leu-
kocytes is shown. 
The LTB4-peak is well separated from the two a\\-trans-
leukotriene B 4 isomers 6-/ratts-leukotriene B 4 and 12-ep/-6-
mms-leukotriene B 4 and the interaction product 5(5), 12(5)-
diHETE. The small concentration of 5(S),12(S)-diHETE 
demonstrates a negligible platelet contamination of the 
PMN preparations. In contrast to the human polymorphonu-
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Figure 1: Reversed phase HPLC chromatograms of arachidonic acidmetabolites produced by 
calcium ionophore A 23187 (20 uM)-stimulated bovine neutrophils (107 cells/ml) in the absen-
ce (I) and presence (II) of 100 \iM anthralin. Solvent system: tetrahydrofuran/methanol/wa-
ter/acetic acid (25:30:45:0.1 by vol.). pH 5.5. Flow rate 0.9 ml/min with detection at 270 nm. 
Peak identification: 1: PGB 2 (internal standard); 2: NDGA (radical scavenger); 3: 6-trans-leu-
kotriene B 4 and 12-epi-6-trans-leukotriene B 4 ; 4: LTB 4 ; 5: 12-epi-6-trans-8-cis-leukotriene B 4 
(5(s),12(s)-diHETE). 
clear leukocytes bovine leukocytes are unable to metabolize 
L T B 4 into 20-hydroxy-LTB428). 
Pretreatment of neutrophils with anthralin (100 |xM) and 
subsequent activation of PMN-5-LO by Ca-ionophore re-
sults in nearly complete absence of the 5-LO products L T B 4 
(Fig. 1) and 5-HETE (not shown). 
A dose response study for anthralin (1) (Fig. 2) revealed 
an inhibition within a narrow concentration range of 20-40 
H-M and a similar IC 5 0 for L T B 4 as well as for 5-HETE was 
obtained. 
Konz. (|iM) 
Figure 2: Dose-dependent inhibition of ionophore-stimulated LT produc-
tion of bovine PMN leukozytes by anthralin. The values represent the aver-
age of two determinations (range < 10%). 
Table 1: Inhibition of 5-LO by anthrones and benzophenones 




1 cone. (flM) 
10 30 
OH OH 0 29 4.23 
1* OH OH 0 33 
2 OH OCOCH3 0 83 3.25 
3 OCOCH3 OCOCH3 30 100 2.40 
4 OH OCH3 0 20 3.44 
5 OCH3 OCH3 91 100 3.12 
6 H N H 2 - 41 2.45 
7 H OH 39 100 3.99 
8 H H 100 100 3.46 





H H 29 3.18 
11 OH OH - 0 3.00 
Inhibition of L T B 4 -resp. 5-HETE*-synthesis. The values represent the 
average of two determinations (range < 10%). - n o t tested 
Tables 1-4 show the effects of several anthralin deriva-
tives and related compounds on the production of 5-LO-pro-
ducts. 
Table 1 summarizes the inhibitory potencies of several 
analogues of anthrone (8) as well as of benzophenone (10). 
Derivatization and substitution of the phenol groups im-
proved the inhibitory efficacy nearly 10-fold as compared 
with anthralin. A net lipophilicity range from log P =? 3-3.5 
seems to be favorable for optimal activity. The activity of 
benzophenone is comparable to that of anthralin (1). 
Table 2: Inhibition of 5-LO by anthralin derivatives and anthraquinones 
compound R 1 Rj Rj inhibition % log P 
cone. (fiM) 
10 30 
12 CH2COOH H H 27 100 3.10 
13 (CH2)2COOH H H 0 65 3.78 
14 CH2OOOH H CH2OOOH - 0 • 
15* CH 2 C00CH 3 H H 0 40 3.93 
16 (CH2)2COOCH3 H H 13 48 4.55 
17* H CH 2OH H 0 53 3.25 
18 H C H 3 H - 0 4.69 
19 OH QH H 0 4.16 
20 OCH3 OCH3 H 0 3.04 
21 H H H 0 3.70 
22 H OH OH 0 4.10 
Inhibition of L T B 4 - resp. 5-HETE*-synthesis. The values represent the 
average of two determinations (range < 10%). - n o t tested 
As seen in Table 2 an overall trend of lower activity for 
dithranol derivatives with side chains at C-2 (C-7) is evi-
dent, despite a favorable log P for some compounds. An-
thraquinones are generally not effective. This holds true 
also for the antipsoriatically active chrysarobin (18). 
The data from Table 3 reveal a modest inhibitory activity 
also for trimethoxyanthracene (24) and l,5-dihydroxy-9-an-
throne (25), whereas the dithranol metabolite bianthrone is 
inactive. 
As seen in Table 4 the 10-((D-carboxyacyl)dithranol deri-
vatives 38 and 39 show an inhibitory efficacy comparable to 
that of the anthrones 5,8, and 9. In contrast acid 37 is only a 
weak inhibitor possibly due to the low log P value of the 
compound. C-10-substituted derivatives without an acyl-
side chain (29-31) possess only marginal activity as well as 
the antipsoriatic active butantrone (33). Esterification of the 
co-carboxyl groups results in a decrease of activity. Deriva-
tives bearing lacton ring structures at C-10 (40-42) show an 
inhibitory potential, which surmounts that of all other com-
pounds tested so far (Tables 4 and 5. This holds true also for 
their inhibitory potential against the 12-lipoxygenase from 
bovine thrombocytes29*. 
Table 5 summarizes the inhibitory potencies of some se-
lected compounds at lower concentrations. 
Table 3: Inhibition of 5-LO by anthrone and anthracene derivatives Table 5: Inhibition of 5-LO by anthrones 
compound R» R 2 R 3 inhibition % lOR P 




'S conc.(fiM) U U • J 10 30 
23 OCOCH3 OCOCH3 OCOCH3 15 2.02 
24* OCH3 OCH3 OCH3 51 78 4.10 
o OH 
HO 
25 1,5-Dihydroxy-9-anthrone 46 100 3.51 









Inhibition of L T B 4 - resp. 5-HETE -synthesis. The values represent the 
average of two determinations (range < 10%). - n o t tested 
Table 4: Influence of C-10-substituted anthralin derivatives on the LTB 4 
production by PMN leukozytes 




R 1 ' R 2 
29 H Br - 0 3.94 
30 H C 2 H 5 - 31 4.37 
31 C 3 H 7 C 3 H 7 - 17 5.19 
32* H COCH3 0 100 3.49 
33 H COC 3 H 7 - 38 4.12 
34 H CO(CH2) 2COOCH3 0 100 3.34 
35 H CXKCH2)3COOCH3 10 100 3.59 
36 H CO(CH2)2COOBz 31 100 4.23 
37 H CO(CH2)2COOH 0 52 2.74 
38 H CO(CH2)3COOH 97 100 2.94 
39 H aKCH 2 )4COOH 100 100 3.14 










Inhibition of L T B 4 - resp. 5-HETE -synthesis. The values represent the 
average of two determinations (range < 10%). - n o t tested 
compound inhibition % 
5 3 \lM 1 uM 
38 25 - 0 
39 36 - 0 
40 83 47 -
41 100 91 42 
42 98 95 15 
8 - 84 -
9 - 40 • 
Inhibition of LTB 4 - resp. 5-HETE -synthesis. The values represent the 
average of two determinations (range < 10%). -"-": not tested 
The stronger efficacy of the 10-acyldithranol derivatives 
as compared to anthralin (1) indicates that these substances 
can not be prodrugs of 1 but are effective by themselves (cf. 
also its inhibitory effects against glucose-6-phosphate-dehy-
drogenase24). These results are supported by experiments 
concerning the metabolism of these substances by mouse 
skin homogenates. Skin homogenates of NMRI-mice (ap-
prox. 35 g) were prepared as described30*, but instead of 
barbital buffer tris buffer (0.1 M, pH 7.4) was used. 
Aliquots taken from the incubation mixture of mouse skin 
homogenate and test compounds were HPLC-analyzed as 
described24). Anthralin (1) was never detected as a metabo-
lite indicating that the 10-acyl linkage was not split enzy-
matically. In the ester derivatives 34 and 35 the ester group 
was hydrolyzed affording the corresponding acids 37 and 
3829), but the phenylogous ß-dicarbonyl system remained 
unaffected. 
Table 6: Effect of substrate concentration on the inhibition of 5-HETE 
production by neutrophils (107/ml)a 
Percent inhibition of 5-HETE production 
exogenic arachidonic acid (uM) 
0 1 3 10 40 80 
anthralin (l)(50^iM) 92 88 74 80 
anthrone (8) (10 ^M) 100 - - 89 76 76 
Acid 12 (20 uM) 100 82 51 0 23 33 
Ester 34 (30 uM) 100 - 100 98 94 88 
Lacton 40 (8 uM) 100 - 100 98 84 50 
Acid 39 (8 \iM) 100 - 95 82 28 0 
a Results represent the average of two determinations, range < 10%. -
not tested 
Effect of different substrate concentrations on the 
inhibition ofleukotriene production 
For several anthrone derivatives the effect of increasing 
arachidonic acid concentrations on the inhibition of 5-
HETE production is shown in Table 6. 
For anthralin (1), anthrone (8), ester 34, and lacton 40 
5-HETE production increases only slightly at high arachi-
donic acid concentrations. In contrast, inhibition by acids 12 
and 39 depends strongly on exogenic substrate concentra-
tion and in the case of 39 is totally absent at higher arachi-
donic acid concentrations. 
Discussion 
In our study we investigated the inhibition of 5-LO from 
bovine polymorphonuclear leukocytes, because they con-
stitute an easily available and inexpensive cellular source 
for this enzyme28). Anthralin (1) showed 50% inhibition at 
37 | iM which is comparable to the IC50 found by Schröder 
with human PMN and was shown to depend strongly upon 
cell density (7-74 |iM!)6*. 12-HETE production by mouse 
epidermal homogenates and human platelets is also in-
hibited by anthralin4* and it was suggested that the drug 
exerts its action by modulation of arachidonic acid metabo-
lism. 
In 1969 Krebs and Schaltegger7) claimed l-hydroxy-9-an-
throne (7) as the minimum basic structure for clinical an-
tipsoriatic activity. Our results show remarkable differences 
between this "minimum structure" concept and the in vitro 
activity of the anthrones in the 5-lipoxygenase test. 
Nonphenolic anthrones with no antipsoriatic activity 
proved to be up to 10-fold more active than anthralin; lipo-
philic parameters may be responsible for this fact, since the 
5-lipoxygenase associates with leukocyte membranes in the 
active state3l). However, the results are in contrast to general 
findings with other substance classes, where replacement of 
the phenolic functions leads to a decrease of inhibitory effi-
cacy32,33*. The inhibition is only slightly influenced by in-
creasing substrate concentrations, which indicate a mainly 
"non-competitive"** way of action. For anthralin derivatives 
with side chains at C-2 (C-7) there might exist a steric hin-
drance for binding at the active site of the enzyme according 
to the binding hypothesis of Summers*4\ This fact may ex-
plain their general low activity (Table 2) as well as the 
strong influence of exogenic substrate concentrations on the 
inhibition of 5-HETE production by 12 (Table 6). 
The inhibitory efficacy of non-phenolic anthrones is partly 
exceeded by that of some 10-co-carboxyacyl-anthralin deri-
vatives as well as derivatives bearing lactone ring structures 
at the C-10-position. Comparable to compound 12, their ac-
tivity seems to depend on the exogenic substrate concentra-
tion and suggests a "competitive"** binding to the active site 
of the 5-lipoxygenase. Interestingly this is not the case for 
ester 34 (Table 6). Recently we have found the lactones 
40-42 to be able to inhibit several cell growth parameters in 
cultured human keratinocytes comparable with the effects 
of anthralin35*. Their clinical efficacy has not yet been es-
tablished on account of legal restrictions. 
Some clinical inactive benzophenone and anthracene deri-
vatives are also capable of inhibiting the 5-lipoxygenase 
enzyme, the efficacy of benzophenone (10) might be due to 
radical scavenging properties. 
Known antipsoriatic agents on the other hand like an-
thralin (1) and butantrone (33) were only weak inhibitors of 
the leukotriene production and chrysarobin (18) was not ef-
fective at all at the concentrations tested. 
Our data suggest that anthralin (1) does not exert its anti-
psoriatic activity through inhibition of leukotriene produc-
tion from polymorphonuclear leukocytes. This view is cor-
roborated by the fact that during treatment with dithranol 
neither 12-HETE nor L T B 4 concentrations were significant-
ly affected in lesional psoriatic skin36*. Consequently the 
suitability of the lipoxygenase assay as an antipsoriatic 
screening system is disputable. 
It should, however, be kept in mind that anthralin (1) also 
influences other functional parameters in human neutro-
phils5*. 
In cultured human keratinocytes the manifestation of the 
biologic responses under treatment with anthralin (1) oc-
curred after a latency phase of some h, which preceded an 
intracellular distribution process with accumulation in the 
mitochondria37*. 
Thus the exposure time to the cells may be crucial for the 
detection of biologic effects. Nevertheless, our finding that 
nonphenolic anthrones and some C-10-acyl derivatives pos-
sess a strong lipoxygenase inhibiting potential, is an unex-
pected result. Their antiphlogistic potential needs further 
evaluation. 
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